BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3076139)

  • 1. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
    Goldberg MR; Sushak CS; Rockhold FW; Thompson WL
    Clin Pharmacol Ther; 1988 Jul; 44(1):78-92. PubMed ID: 3292105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schirger A; Fisher LD; Shub C; Collins JB; Spiekerman RE
    Eur J Clin Pharmacol; 1986; 31(2):133-41. PubMed ID: 3803413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
    Sterndorff B; Johansen P
    Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
    Carlsen JE; Jensen HA; Rehling M; Lund JO; Trap-Jensen J
    Drugs; 1988; 36 Suppl 7():55-63. PubMed ID: 3076136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
    Abraham PA; Halstenson CE; Matzke GR; Keane WF
    J Clin Hypertens; 1987 Dec; 3(4):439-51. PubMed ID: 3330986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
    Sterndorff B; Johansen P
    Acta Med Scand; 1988; 224(4):329-36. PubMed ID: 3188983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
    Jackson B; Morgan TO; Gibson J; Anderson A
    Drugs; 1987; 34 Suppl 3():109-19. PubMed ID: 2894971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    Friedel HA; Brogden RN
    Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension. Pinacidil-Prazosin and Pinacidil-Placebo Research Groups, Lilly Research Laboratories.
    Rockhold FW; Goldberg MR; Thompson WL
    J Lab Clin Med; 1989 Dec; 114(6):646-54. PubMed ID: 2687423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension.
    Jürgensen HJ
    Drugs; 1988; 36 Suppl 7():67-9. PubMed ID: 3076138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.